BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31617267)

  • 1. A case of renal cell carcinoma unclassified with medullary phenotype without detectable gene deletion.
    Tsuzuki S; Kataoka TR; Ito H; Ueshima C; Asai S; Yokoo H; Haga H
    Pathol Int; 2019 Dec; 69(12):710-714. PubMed ID: 31617267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Unclassified Renal Cell Carcinoma With Medullary Phenotype and
    Valeri M; Cieri M; Elefante GM; De Carlo C; Rudini N; Lughezzani G; Buffi NM; Terracciano LM; Colombo P
    Front Med (Lausanne); 2022; 9():835599. PubMed ID: 35198580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Cell Carcinoma, Unclassified with Medullary Phenotype and Synchronous Renal Clear Cell Carcinoma Present in a Patient with No Sickle Cell Trait/Disease: Diagnostic and Therapeutic Challenges.
    Lai JZ; Lai HH; Cao D
    Anticancer Res; 2018 Jun; 38(6):3757-3761. PubMed ID: 29848739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma, unclassified with medullary phenotype: poorly differentiated adenocarcinomas overlapping with renal medullary carcinoma.
    Sirohi D; Smith SC; Ohe C; Colombo P; Divatia M; Dragoescu E; Rao P; Hirsch MS; Chen YB; Mehra R; Amin MB
    Hum Pathol; 2017 Sep; 67():134-145. PubMed ID: 28716439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Cell Carcinoma Unclassified with Medullary Phenotype in a Patient with Neurofibromatosis Type 2.
    Sarkar S; Throckmorton W; Bingham R; Msaouel P; Genovese G; Slopis J; Rao P; Sadighi Z; Herzog CE
    Curr Oncol; 2023 Mar; 30(3):3355-3365. PubMed ID: 36975468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMARCB1 regulates the hypoxic stress response in sickle cell trait.
    Soeung M; Perelli L; Chen Z; Dondossola E; Ho IL; Carbone F; Zhang L; Khan H; Le CN; Zhu C; Peoples MD; Feng N; Jiang S; Zacharias NM; Minelli R; Shapiro DD; Deem AK; Gao S; Cheng EH; Lucchetti D; Walker CL; Carugo A; Giuliani V; Heffernan TP; Viale A; Tannir NM; Draetta GF; Msaouel P; Genovese G
    Proc Natl Acad Sci U S A; 2023 May; 120(21):e2209639120. PubMed ID: 37186844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal medullary carcinoma in a young mixed-race man in Japan.
    Toriyama A; Izumi H; Tomita S; Nagashima Y; Ueda Y; Aoki Y; Tsujimura A; Yao T; Hino O
    Pathol Int; 2019 Apr; 69(4):241-245. PubMed ID: 30843648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma.
    Msaouel P; Hong AL; Mullen EA; Atkins MB; Walker CL; Lee CH; Carden MA; Genovese G; Linehan WM; Rao P; Merino MJ; Grodman H; Dome JS; Fernandez CV; Geller JI; Apolo AB; Daw NC; Hodges HC; Moxey-Mims M; Wei D; Bottaro DP; Staehler M; Karam JA; Rathmell WK; Tannir NM
    Clin Genitourin Cancer; 2019 Feb; 17(1):1-6. PubMed ID: 30287223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
    Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
    Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinctive mechanisms underlie the loss of SMARCB1 protein expression in renal medullary carcinoma: morphologic and molecular analysis of 20 cases.
    Jia L; Carlo MI; Khan H; Nanjangud GJ; Rana S; Cimera R; Zhang Y; Hakimi AA; Verma AK; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE; Gartrell BA; Chen YB
    Mod Pathol; 2019 Sep; 32(9):1329-1343. PubMed ID: 30980040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Model Linking Sickle Cell Hemoglobinopathies and SMARCB1 Loss in Renal Medullary Carcinoma.
    Msaouel P; Tannir NM; Walker CL
    Clin Cancer Res; 2018 May; 24(9):2044-2049. PubMed ID: 29440190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Xp11.2 translocation renal cell carcinoma with SMARCB1 (INI1) inactivation in adult end-stage renal disease: a case report.
    Yu L; Li J; Xu S; Navia Miranda M; Wang G; Duan Y
    Diagn Pathol; 2016 Oct; 11(1):98. PubMed ID: 27733182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments.
    Wei D; Yang Y; Ricketts CJ; Vocke CD; Ball MW; Sourbier C; Wangsa D; Wangsa D; Guha R; Zhang X; Wilson K; Chen L; Meltzer PS; Ried T; Thomas CJ; Merino MJ; Linehan WM
    Genes Chromosomes Cancer; 2020 Aug; 59(8):472-483. PubMed ID: 32259323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary Carcinomas.
    Calderaro J; Masliah-Planchon J; Richer W; Maillot L; Maille P; Mansuy L; Bastien C; de la Taille A; Boussion H; Charpy C; Jourdain A; Bléchet C; Pierron G; Gentien D; Choudat L; Tournigand C; Delattre O; Allory Y; Bourdeaut F
    Eur Urol; 2016 Jun; 69(6):1055-61. PubMed ID: 26433572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts].
    Agaimy A; Hartmann A
    Pathologe; 2021 Nov; 42(6):571-577. PubMed ID: 34609565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of SMARCB1/INI-1 expression in collecting duct carcinoma.
    Elwood H; Chaux A; Schultz L; Illei PB; Baydar DE; Billis A; Sharma R; Argani P; Epstein JI; Netto GJ
    Urology; 2011 Aug; 78(2):474.e1-5. PubMed ID: 21705046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
    Carlo MI; Chaim J; Patil S; Kemel Y; Schram AM; Woo K; Coskey D; Nanjangud GJ; Voss MH; Feldman DR; Hsieh JJ; Hakimi AA; Chen YB; Motzer RJ; Lee CH
    Clin Genitourin Cancer; 2017 Dec; 15(6):e987-e994. PubMed ID: 28558987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal medullary carcinomas depend upon
    Hong AL; Tseng YY; Wala JA; Kim WJ; Kynnap BD; Doshi MB; Kugener G; Sandoval GJ; Howard TP; Li J; Yang X; Tillgren M; Ghandi M; Sayeed A; Deasy R; Ward A; McSteen B; Labella KM; Keskula P; Tracy A; Connor C; Clinton CM; Church AJ; Crompton BD; Janeway KA; Van Hare B; Sandak D; Gjoerup O; Bandopadhayay P; Clemons PA; Schreiber SL; Root DE; Gokhale PC; Chi SN; Mullen EA; Roberts CW; Kadoch C; Beroukhim R; Ligon KL; Boehm JS; Hahn WC
    Elife; 2019 Mar; 8():. PubMed ID: 30860482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Renal Medullary Carcinoma.
    Su Y; Hong AL
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.